Published on 3 May 2024 on Zacks via Yahoo Finance
Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know
Nautilus Biotechnology, Inc. (NAUT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.